Selected article for: "clinical prevention and control clinical prevention"
Author: Fu, Sha; Fu, Xiaoyu; Song, Yang; Li, Min; Pan, Pin-hua; Tang, Tao; Zhang, Chunhu; Jiang, Tiejian; Tan, Deming; Fan, Xuegong; Sha, Xinping; Ma, Jingdong; Huang, Yan; Li, Shaling; Zheng, Yixiang; Qian, Zhaoxin; Xiong, Zeng; Xiao, Lizhi; Long, Huibao; Chen, Jianghai; Ouyang, Yi
Title: Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China
  • Cord-id: 4989atst
  • Document date: 2020_4_6
    • ID: 4989atst
    Snippet: Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has progressed to a pandemic associated with substantial morbidity and mortality. The WHO and the United States Center for Disease Control and Prevention (CDC) have issued interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19), but there is limited data on the virologic and clinical characteristics for prognosis of severe COVID-19. Methods: A total of 50 patients with severe C
    Document: Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has progressed to a pandemic associated with substantial morbidity and mortality. The WHO and the United States Center for Disease Control and Prevention (CDC) have issued interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19), but there is limited data on the virologic and clinical characteristics for prognosis of severe COVID-19. Methods: A total of 50 patients with severe COVID-19 were divided into good and poor recovery groups. The dynamic viral shedding and serological characteristics of SARS-CoV-2 were explored. The risk factors associated with poor recovery and lung lesion resolutions were identified. In addition, the potential relationships among the viral shedding, the pro-inflammatory response, and lung lesion evolutions were characterized. Results: A total of 58% of the patients had poor recovery and were more likely to have a prolonged interval of viral shedding. The longest viral shedding was 57 days after symptom onset. Older age, hyperlipemia, hypoproteinemia, corticosteroid therapy, consolidation on chest computed-tomography (CT), and prolonged SARS-CoV-2 IgM positive were all associated with poor recovery. Additionally, the odds of impaired lung lesion resolutions were higher in patients with hypoproteinemia, hyperlipemia, and elevated levels of IL-4 and ferritin. Finally, viral shedding and proinflammatory responses were closely correlated with lung lesion evolutions on chest CT. Conclusions Patients with severe COVID-19 have prolonged SARS-CoV-2 infection and delayed intermittent viral shedding. Older age, hyperlipemia, hypoproteinemia, corticosteroid usage, and prolonged SARS-CoV-2 IgM positive might be utilized as predicative factors for the patients with poor recovery.

    Search related documents:
    Co phrase search for related documents
    • active phase and liver injury: 1
    • active phase and lung damage: 1, 2, 3, 4
    • active viral replication and long duration: 1
    • active viral replication and lung damage: 1, 2
    • active virus replication and lung damage: 1
    • active virus replication and lung involvement: 1, 2
    • acute phase and liver dysfunction: 1, 2, 3, 4
    • acute phase and liver injury: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and long duration: 1, 2, 3, 4, 5, 6
    • acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute phase and lung imaging: 1, 2, 3
    • acute phase and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver dysfunction and lung damage: 1, 2
    • liver dysfunction and lung involvement: 1
    • liver injury and long duration: 1
    • liver injury and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver injury and lung imaging: 1
    • liver injury and lung involvement: 1, 2, 3, 4, 5, 6, 7
    • long duration and lung damage: 1, 2